Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma

Vahakn B. Shahinian, Yong Fang Kuo, Jean L. Freeman, Eduardo Orihuela, James Goodwin

Research output: Contribution to journalArticle

255 Citations (Scopus)

Abstract

BACKGROUND. The role of androgen deprivation therapy in prostate carcinoma is controversial in earlier stages of disease. The authors examined the time trends and patterns of use for androgen deprivation in the form of gonadotropin-releasing hormone (GnRH) agonists or orchiectomy, in population-based tumor registries. METHODS. Data were obtained from the linked Surveillance, Epidemiology and End Results-Medicare database. A total of 100,274 men with prostate carcinoma diagnosed from 1991 through 1999 were selected. The main outcome was the proportion of men who received ≥ 1 dose of a GnRH agonist in the first 6 months of diagnosis. This was plotted by year and stratified for age, grade, stage as well as primary versus adjuvant usage. Multiple logistic regression was used to examine predictors of GnRH agonist use in the subset of patients with localized cancer. RESULTS. There was a consistent increase in GnRH agonist use by year for all ages, stages, and grades. Even in men ≥ 80 years with localized stage and low to moderate grade tumors, primary GnRH agonist use increased over the study period, from 3.7% in 1991 to 30.9% in 1999 (P < 0.001). The multivariable analysis showed that significant variability in GnRH agonist use existed among SEER geographic regions. CONCLUSIONS. The use of GnRH agonists for prostate carcinoma increased dramatically during the 1990s. This increase occurred across all stages and histologic grades of prostate carcinoma, and was greatest in patients ≥ 80 years.

Original languageEnglish (US)
Pages (from-to)1615-1624
Number of pages10
JournalCancer
Volume103
Issue number8
DOIs
StatePublished - Apr 15 2005

Fingerprint

Gonadotropin-Releasing Hormone
Prostate
Carcinoma
Therapeutics
Androgens
Neoplasms
Orchiectomy
Medicare
Registries
Epidemiology
Logistic Models
Databases
Population

Keywords

  • Epidemiology and End Results program
  • Goserelin
  • Leuprolide
  • Medicare
  • Prostatic neoplasm
  • Surveillance

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. / Shahinian, Vahakn B.; Kuo, Yong Fang; Freeman, Jean L.; Orihuela, Eduardo; Goodwin, James.

In: Cancer, Vol. 103, No. 8, 15.04.2005, p. 1615-1624.

Research output: Contribution to journalArticle

Shahinian, Vahakn B. ; Kuo, Yong Fang ; Freeman, Jean L. ; Orihuela, Eduardo ; Goodwin, James. / Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. In: Cancer. 2005 ; Vol. 103, No. 8. pp. 1615-1624.
@article{650a981b00ec4499bd8aecb41235ca39,
title = "Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma",
abstract = "BACKGROUND. The role of androgen deprivation therapy in prostate carcinoma is controversial in earlier stages of disease. The authors examined the time trends and patterns of use for androgen deprivation in the form of gonadotropin-releasing hormone (GnRH) agonists or orchiectomy, in population-based tumor registries. METHODS. Data were obtained from the linked Surveillance, Epidemiology and End Results-Medicare database. A total of 100,274 men with prostate carcinoma diagnosed from 1991 through 1999 were selected. The main outcome was the proportion of men who received ≥ 1 dose of a GnRH agonist in the first 6 months of diagnosis. This was plotted by year and stratified for age, grade, stage as well as primary versus adjuvant usage. Multiple logistic regression was used to examine predictors of GnRH agonist use in the subset of patients with localized cancer. RESULTS. There was a consistent increase in GnRH agonist use by year for all ages, stages, and grades. Even in men ≥ 80 years with localized stage and low to moderate grade tumors, primary GnRH agonist use increased over the study period, from 3.7{\%} in 1991 to 30.9{\%} in 1999 (P < 0.001). The multivariable analysis showed that significant variability in GnRH agonist use existed among SEER geographic regions. CONCLUSIONS. The use of GnRH agonists for prostate carcinoma increased dramatically during the 1990s. This increase occurred across all stages and histologic grades of prostate carcinoma, and was greatest in patients ≥ 80 years.",
keywords = "Epidemiology and End Results program, Goserelin, Leuprolide, Medicare, Prostatic neoplasm, Surveillance",
author = "Shahinian, {Vahakn B.} and Kuo, {Yong Fang} and Freeman, {Jean L.} and Eduardo Orihuela and James Goodwin",
year = "2005",
month = "4",
day = "15",
doi = "10.1002/cncr.20955",
language = "English (US)",
volume = "103",
pages = "1615--1624",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma

AU - Shahinian, Vahakn B.

AU - Kuo, Yong Fang

AU - Freeman, Jean L.

AU - Orihuela, Eduardo

AU - Goodwin, James

PY - 2005/4/15

Y1 - 2005/4/15

N2 - BACKGROUND. The role of androgen deprivation therapy in prostate carcinoma is controversial in earlier stages of disease. The authors examined the time trends and patterns of use for androgen deprivation in the form of gonadotropin-releasing hormone (GnRH) agonists or orchiectomy, in population-based tumor registries. METHODS. Data were obtained from the linked Surveillance, Epidemiology and End Results-Medicare database. A total of 100,274 men with prostate carcinoma diagnosed from 1991 through 1999 were selected. The main outcome was the proportion of men who received ≥ 1 dose of a GnRH agonist in the first 6 months of diagnosis. This was plotted by year and stratified for age, grade, stage as well as primary versus adjuvant usage. Multiple logistic regression was used to examine predictors of GnRH agonist use in the subset of patients with localized cancer. RESULTS. There was a consistent increase in GnRH agonist use by year for all ages, stages, and grades. Even in men ≥ 80 years with localized stage and low to moderate grade tumors, primary GnRH agonist use increased over the study period, from 3.7% in 1991 to 30.9% in 1999 (P < 0.001). The multivariable analysis showed that significant variability in GnRH agonist use existed among SEER geographic regions. CONCLUSIONS. The use of GnRH agonists for prostate carcinoma increased dramatically during the 1990s. This increase occurred across all stages and histologic grades of prostate carcinoma, and was greatest in patients ≥ 80 years.

AB - BACKGROUND. The role of androgen deprivation therapy in prostate carcinoma is controversial in earlier stages of disease. The authors examined the time trends and patterns of use for androgen deprivation in the form of gonadotropin-releasing hormone (GnRH) agonists or orchiectomy, in population-based tumor registries. METHODS. Data were obtained from the linked Surveillance, Epidemiology and End Results-Medicare database. A total of 100,274 men with prostate carcinoma diagnosed from 1991 through 1999 were selected. The main outcome was the proportion of men who received ≥ 1 dose of a GnRH agonist in the first 6 months of diagnosis. This was plotted by year and stratified for age, grade, stage as well as primary versus adjuvant usage. Multiple logistic regression was used to examine predictors of GnRH agonist use in the subset of patients with localized cancer. RESULTS. There was a consistent increase in GnRH agonist use by year for all ages, stages, and grades. Even in men ≥ 80 years with localized stage and low to moderate grade tumors, primary GnRH agonist use increased over the study period, from 3.7% in 1991 to 30.9% in 1999 (P < 0.001). The multivariable analysis showed that significant variability in GnRH agonist use existed among SEER geographic regions. CONCLUSIONS. The use of GnRH agonists for prostate carcinoma increased dramatically during the 1990s. This increase occurred across all stages and histologic grades of prostate carcinoma, and was greatest in patients ≥ 80 years.

KW - Epidemiology and End Results program

KW - Goserelin

KW - Leuprolide

KW - Medicare

KW - Prostatic neoplasm

KW - Surveillance

UR - http://www.scopus.com/inward/record.url?scp=16844373505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16844373505&partnerID=8YFLogxK

U2 - 10.1002/cncr.20955

DO - 10.1002/cncr.20955

M3 - Article

VL - 103

SP - 1615

EP - 1624

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -